New cell therapy targets common cancer mutation in early trial
NCT ID NCT07594067
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them to better recognize and attack cancer cells, and infusing them back. The main goals are to check safety, find the right dose, and see if the cells can be made successfully.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TCR1188-ABC cells (engineered immune cells) plus chemotherapy (fludarabine and cyclophosphamide)
- What this could lead to
- If successful, this could point toward a new treatment option for several hard-to-treat cancers with a specific KRAS mutation.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, focused on safety and dosing. It is too soon to know if it will work, and there are risks of serious side effects from the cell therapy and chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can we predict who will survive a bowel surgery leak?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?